OB

Oxford Biomedica

Organization

Heard in 3 episodes across 2 shows since Aug 2026

Oxford Biomedica (OXB) is a leading gene and cell therapy company specializing in the development and manufacturing of gene-based medicines. Operating as a contract development and manufacturing organization (CDMO), it provides critical viral vector solutions to power progressive cell and gene therapies globally.

Learn more

Episodes

3
across 2 shows

First heard

Aug 2026

Expert statements

5
5 negative

Episodes per month

Public PodLume episodes featuring it, over the last year.

Show the data
MonthEpisodes
Nov 20250
Dec 20250
Jan 20260
Feb 20260
Mar 20260
Apr 20260
May 20260
Jun 20260
Jul 20260
Aug 20263
Sep 20260
Oct 20260

What experts have said about Oxford Biomedica

5 statements · 5 negative

  1. Louise MoonNegativeAug 18, 2026· Stock Movers

    Oxford Biomedica cut its full-year revenue and profitability guidance.

    “they cut their full year revenue and profitability guidance.”

    Listen at 4:05

    Open the episode · Frasers Group Up, Royal Unibrew Drops, OXB Down
  2. Paul ScottNegativeAug 7, 2026· UK Small/Mid Caps with Paul Scott

    Oxford Biomedica is loss-making and consuming cash, complicating valuation.

    “It's loss-making and cash-burning, so it's quite a leap of faith here to actually value it.”

    Listen at 14:59

    Open the episode · Paul's Podcast - Fri 7 Aug 2026
  3. Paul ScottNegativeAug 7, 2026· UK Small/Mid Caps with Paul Scott

    Oxford Biomedica is currently far below its revenue target.

    “it's nowhere near that level at the moment.”

    Listen at 15:32

    Open the episode · Paul's Podcast - Fri 7 Aug 2026
See all 5 statements →

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Episodes

3 episodes featuring Oxford Biomedica, newest first

Oxford Biomedica · PodLume